For Advanced Sarcoma, Adding Lymphodepletion to HER2-Targeted CAR T-Cell Therapy Excites

A phase I trial evaluated the safety and efficacy of adding  lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma.

Source: CancerNetwork - April 9, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news